Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
national blog main
san francisco blog main
129
×
life sciences
san francisco top stories
national top stories
boston blog main
biotech
boston top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
raleigh-durham blog main
wisconsin blog main
national
seattle blog main
wisconsin top stories
detroit blog main
raleigh-durham top stories
detroit top stories
seattle top stories
texas blog main
texas top stories
boulder/denver blog main
indiana blog main
fda
boulder/denver top stories
indiana top stories
clinical trials
startups
deals
cancer
san francisco
pfizer
eli lilly
novartis
investing
vc
gene therapy
merck
What
drug
bio
roundup
cancer
new
medicine
medicines
medical
drugs
fda
ipo
companies
week
therapeutics
life
startup
biotech
gene
million
company
science
therapy
disease
healthcare
patients
based
crispr
deal
today
approval
approved
big
data
days
developing
health
help
long
pharmaceutical
research
Language
unset
unknown
Current search:
" san francisco blog main "
×
@xconomy.com
3 months ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 months ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 months ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 months ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
4 months ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 months ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
4 months ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 months ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 months ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 months ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 months ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
6 months ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
6 months ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
9 months ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
10 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
11 months ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
11 months ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
11 months ago
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
@xconomy.com
11 months ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
11 months ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
11 months ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
1 year ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
1 year ago
Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy
@xconomy.com
1 year ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
1 year ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
1 year ago
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal
@xconomy.com
1 year ago
Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow
@xconomy.com
1 year ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
1 year ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com
1 year ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
1 year ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com
1 year ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
1 year ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
1 year ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
1 year ago
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?
@xconomy.com
1 year ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
1 year ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
1 year ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
1 year ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
1 year ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
1 year ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
1 year ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
1 year ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
1 year ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
1 year ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
1 year ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
1 year ago
White House Floats Canadian Import Plan But Excludes Many Costly Drugs
@xconomy.com
1 year ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
First
Prev
Page 1
(current)
Next
Last